A patient on Synjardy (metformin and empagliflozin) twice daily has recurrent urinary tract infections; after discontinuing the SGLT2 inhibitor, what glucose‑lowering agent should be added to metformin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Add a GLP-1 Receptor Agonist to Metformin

After discontinuing the SGLT2 inhibitor due to recurrent UTIs, add a long-acting GLP-1 receptor agonist (such as dulaglutide, liraglutide, or semaglutide) to metformin for this patient.

Rationale for GLP-1 RA Selection

The KDIGO 2020 guidelines explicitly recommend that for patients with type 2 diabetes and CKD who cannot use SGLT2 inhibitors, a long-acting GLP-1 receptor agonist should be added to metformin 1. This recommendation is particularly strong (Grade 1B) and prioritizes agents with documented cardiovascular benefits 1.

Why Not Resume the SGLT2 Inhibitor?

While SGLT2 inhibitors like empagliflozin have excellent cardiovascular and renal benefits, recurrent UTIs represent a legitimate reason for discontinuation 1. The guidelines acknowledge that SGLT2 inhibitors increase the risk of genitourinary infections, with genital mycotic infections occurring in approximately 6% of patients 2. Although the evidence on whether to continue SGLT2 inhibitors after UTIs is mixed—with one recent study suggesting continuation may not increase recurrent UTI risk 3—the patient's quality of life and infection burden must be prioritized.

Specific GLP-1 RA Recommendations

Preferred agents with proven cardiovascular benefit 2:

  • Dulaglutide (0.75-1.5 mg once weekly): No dose adjustment needed for renal impairment; can be used with eGFR >15 mL/min/1.73 m²
  • Liraglutide (0.6-1.8 mg once daily): No dose adjustment required; proven MACE reduction
  • Semaglutide (0.5-1 mg once weekly injectable, or 3-14 mg oral daily): No dose adjustment needed; strong cardiovascular outcomes data

Dosing Strategy

Start low and titrate slowly to minimize gastrointestinal side effects 1:

  • Begin with the lowest available dose
  • Increase gradually every 4 weeks based on tolerance
  • GI symptoms (nausea, vomiting) are common initially but typically improve with slow titration

Continue Metformin

Metformin should be continued unless contraindicated 1. The KDIGO guidelines strongly recommend metformin for patients with type 2 diabetes and CKD with eGFR ≥30 mL/min/1.73 m² (Grade 1B recommendation) 1. Dose adjustments are only needed if eGFR falls below 45 mL/min/1.73 m².

Alternative Considerations (Lower Priority)

If GLP-1 RAs are not tolerated or contraindicated:

DPP-4 inhibitors (such as linagliptin or sitagliptin with dose adjustment) are reasonable alternatives 1, 2:

  • Lower hypoglycemia risk
  • Weight neutral
  • No increased UTI risk
  • However, they lack the cardiovascular and renal benefits of GLP-1 RAs

Do not use both a GLP-1 RA and DPP-4 inhibitor together—they work through similar mechanisms and combination provides no additional benefit 1.

Key Clinical Pitfalls to Avoid

  1. Do not restart the SGLT2 inhibitor immediately without addressing the recurrent UTI pattern—while some data suggest continuation may be safe 3, the patient's repeated infections indicate poor tolerance

  2. Avoid sulfonylureas as they increase hypoglycemia risk and lack cardiovascular/renal benefits 1

  3. Monitor for GLP-1 RA side effects: Start with low doses and titrate slowly; most GI symptoms resolve within 4-8 weeks 1

  4. Assess renal function before initiating therapy and monitor periodically, though most GLP-1 RAs require no dose adjustment 2

  5. Consider insulin only if glycemic targets are not met with metformin plus GLP-1 RA, as it increases hypoglycemia risk and requires more intensive monitoring 4

Related Questions

In a 59-year-old male with diabetes mellitus and hypertension, currently taking metformin 1000 mg twice daily and empagliflozin (Jardiance) 25 mg daily, who has elevated LDL cholesterol, elevated triglycerides, vitamin D deficiency, and an HbA1c of 7.1%, what is the optimal management plan?
How should I manage a 60-year-old patient with type 2 diabetes mellitus on empagliflozin 25 mg and metformin who now has a blood glucose of 301 mg/dL (≈16.7 mmol/L)?
In a 67-year-old male with type 2 diabetes mellitus who developed rash and pruritus immediately after starting Jardiance (empagliflozin) 25 mg daily and Januvia (sitagliptin) 100 mg daily, what management steps should be taken?
In a 38‑year‑old patient with type 2 diabetes, hypertension and hyperlipidemia who is taking empagliflozin 10 mg daily and metformin extended‑release (metformin XR) 2 g with the evening meal, is the metformin XR 2 g dose sufficient given fasting glucose ranging from 5.8 to 9 mmol/L?
For a 49-year-old male with diabetes, HbA1c 8.4%, currently on metformin and Invokana (canagliflozin) 100 mg daily but without insurance coverage for Invokana, what alternative medication can replace it?
Should a patient with a cough that worsens when lying down and no nasal congestion be treated with a proton‑pump inhibitor (omeprazole)?
What is the compounded prescription for a 5% permethrin cream to treat scabies in a 13‑month‑old child?
A patient on olanzapine 20 mg by mouth at bedtime has hypotension and bradycardia; should the dosing be changed to twice daily?
What steps should be taken to improve glycemic control in a patient with type 1 diabetes mellitus using an insulin pump delivering 80 units of lispro daily and having an uncontrolled hemoglobin A1c?
What is the definition of erythrocytosis?
For a 70‑kg type 1 diabetic using an insulin pump, should I increase total daily insulin lispro to 120 units?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.